GLP-1 RA Drug Clinical Development
Tigermed's GLP-1 RA drug development solution offers integrated, full-life-cycle services from preclinical to Phase IV clinical development. Our capabilities cover non-clinical research (animal efficacy, toxicology, DMPK), regulatory submission, clinical development strategy, medical writing, medical monitoring, operations, biostatistics, clinical pharmacology and quantitative pharmacology, drug safety surveillance, comparator drug procurement, central laboratory, and more. In addition, through digital technologies and innovative models such as DCT (Decentralized Clinical Trials), remote monitoring combined with on-site monitoring, we can effectively enhance the quality and efficiency of clinical development while reducing R&D costs.
Over the years, our team has collaborated with over 200 research centers across China on GLP-1 receptor agonist clinical trials, helping GLP-1 drugs operate efficiently and rapidly, contributing to the successful approval of innovative drugs for a wide range of indications, including diabetes, obesity, cardiovascular diseases, non-alcoholic steatohepatitis (NASH), and chronic kidney disease, thereby benefiting patients.
Through Tigermed's innovative drug integrated R&D service platform, we look forward to promoting the launch of more GLP-1 drugs, accelerating the development of breakthrough therapies, and driving transformation in future disease treatment and health management.
